现代医药卫生2016，Vol.32Issue(16)：2459-2461,2464,4.DOI:10.3969/j.issn.1009-5519.2016.16.003
经支气管动脉灌注化疗联合栓塞术治疗中晚期肺癌的临床疗效
Clinical efficacy of bronchial arterial perfusion chemotherapy embolization in treating mid-stage and advanced lung cancer
摘要
Abstract
Objective To investigate the clinical efficacy of bronchial arterial perfusion chemotherapy embolization (BACE) in treating mid-stage and advanced lung cancer (LC). Methods One hundred cases of mid-stage and advanced LC treat-ed in our hospital from July 2011 to June 2013 were included in this study and divided into the BACE group and systemic venous chemotherapy(SVC) group according to the random numbers generated by computer,50 cases in each group. The patients in the BACE group were given the BACE treatment at first,and then SVC was performed,while the SCV group was only performed the SCV treatment. The clinical efficacies,levels of T lymphocyte factors including CD3+,CD4+,CD8+and CD4+/CD8+,the one-year and three-year survival rates and adverse reactions were compared between the two groups. Results After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the two groups were increased,while CD8+level was decreased,the difference com-pared with before treatment was statistically significant(P<0.05);the levels of CD3+,CD4+and CD4+/CD8+in the BACE group were higher than those in the SVC group,while the CD8+level was lower than that in the SVC group,the difference was statisti-cally significant(P<0.05). The total remission rate in the BACE group was 92.00%(46/50),which was higher than 76.00%(38/50) in the SVC group,the difference was statistically significant(P<0.05). The one-year survival rate and three-year survival rate in the BACE group were 92.00%(46/50) and 74.00%(37/50),which were higher than 76.00%(38/50) and 54.00%(27/50),the difference was statistically significant(P<0.05). The occurrence rate of adverse reactions had no statistical difference between the BACE group and the SVC group. Conclusions BACE in treating mid-stage and advanced LC can effectively correct the cell-mediated immunity imbalance state of the body,the clinical efficacy is remarkable,the one-year or three-year survival rate is high,and the adverse effects rate during treatment has no significant difference from SVC treatment,so BACE is worthy of applica-tion in clinic.关键词
肺肿瘤/放射摄影术,胸部/输注,动脉内/栓塞,治疗性/治疗结果Key words
Lung neoplasms/Radiography,thoracic/Infusions,intra-arterial/Embolization,therapeutic/Treatment outcome引用本文复制引用
任柏沉,孙建,张维..经支气管动脉灌注化疗联合栓塞术治疗中晚期肺癌的临床疗效[J].现代医药卫生,2016,32(16):2459-2461,2464,4.基金项目
四川省卫生厅资助项目（11ZA230）。 （）
